PRTK

Paratek Pharmaceuticals, Inc. (PRTK) | Rumor.io

Paratek Pharmaceuticals

PRTK

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about PRTK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

Sep 18

Paratek Pharmaceuticals ($PRTK) stockholders approved the acquisition by Gurnet Point Capital and Novo Holdings A/S.
Lawsuits have been filed against Paratek Pharmaceuticals ($PRTK) by investors challenging the merger.
The acquisition was approved with a 3:1 vote in favor, with some investors expressing concerns and disappointment with the deal.

Generated by AI

Sentiment

Of the messages about PRTK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100%	100% +11.76
Bearish	0%	0%	0%	0% -11.76

Bullish· Mar 31

Paratek Pharmaceuticals, Inc. ($PRTK) has had a strong week, with new stakeholders and a potential activist investor battle contributing to its growth.
Insider buying activity has been significant, with multiple posts mentioning large purchases and a potential debt restructuring deal in the works.
The company's stock price is expected to break through $3, with some analysts setting a price target of $14, citing the stock's strong momentum and low float.

Bearish· Jun 6

The proposed acquisition price of $3.00 per share is considered a robbery and a low-ball offer, resulting in a significant loss for shareholders.
The company's management is accused of failing to act in the best interests of shareholders, prioritizing their own bonuses and cash payouts over the company's value.
The deal's prospects are deemed unlikely to pass the shareholder vote, with many investors expressing outrage and disappointment at the proposed terms.

Generated by AI

Topics

Of the messages about PRTK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Earnings· Aug 1

Paratek Pharmaceuticals is set to release earnings after the market closes on Thursday.
Analysts expect Paratek Pharmaceuticals to report -0.93 EPS.
Earnings release timing: after the market closes on Thursday.

Analysts· Apr 4

BTIG raised Paratek Pharmaceuticals' (PRTK) price target to $56, citing positive top-line results from Omadacycline's Phase 3 CABP trial.
Wedbush initiated coverage of PRTK with an Outperform rating and set a price target of $30, which was later raised to $34.
Analysts have given an average rating of Buy to Paratek Pharmaceuticals (PRTK), with some firms setting price targets as high as $56.

Announcements· Jun 6

Paratek Pharmaceuticals, Inc. ($PRTK) will be acquired by Gurnet Point Capital and Novo Holdings for $2.15 per share in cash, plus a Contingent Value Right of $0.85 per share.
The acquisition is valued at approximately $462 million, including the assumption of debt and the full payment of a Contingent Value Right.
The deal is contingent upon Paratek achieving $320 million in U.S. NUZYRA net sales by December 31, 2026, with the upfront payment representing a premium of 41% over the closing price of Paratek's common stock as of May 31, 2023.

Technical Analysis· Oct 4

$PRTK is nearing an ascending triangle breakout level.
The stock has broken the ascending triangle resistance and is showing strong uptrending momentum with good volume.
A bullish crossover on the TSI (True Strength Index) on the monthly chart is expected to confirm a longer-term uptrend for $PRTK.

Generated by AI

Community

Of the messages about PRTK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	60%
Newcomers	0%	0%	0%	40%

Regulars· Jun 6

Paratek Pharmaceuticals, Inc. (PRTK) has been acquired by Novo Holdings and Gurnet Point Capital.
The acquisition is a result of Paratek being low on cash and in need of a buyout.
The trading halt on PRTK has been resolved, allowing the acquisition to move forward.

Newcomers· Aug 18

The newcomer is focusing on the potential for a significant price increase after the FDA news, with some setting a price target of $28.
The newcomer is optimistic about the asset's future due to the Orphan Drug Designation for NUZYRA, with some comparing it to the 550% move in $VRPX after similar news.
The newcomer is considering adding more shares, as the asset is considered cheap at the current price, and Orphan Drug companies are seen as the most profitable area of all drug types.

Generated by AI

Also Discussed

Investors talking about PRTK also mention

#	Name	Attention
1	Puma Biotechnology, Inc.PBYI	0%0
2	ITCI - Intra-Cellular Therapies, Inc.	——
3	BLCM - Bellicum Pharmaceuticals, Inc.	——
4	SCYNEXIS, Inc. Common StockSCYX	0%-0.02
5	CDTX - Cidara Therapeutics, Inc.	——
6	Verastem Inc.VSTM	0%0
7	Theravance Biopharma Inc.TBPH	0%new
8	Neurocrine Biosciences, Inc.NBIX	0%new
9	EGRX - Eagle Pharmaceuticals, Inc.	——
10	BPMC - Blueprint Medicines Corporation	——